A qualitative and quantitative analysis of von Willebrand factor contained in a very high-purity plasma-derived FVIII concentrate

Vox Sanguinis

Volumn 103, Issue 1, 2012, Pages 35-41

  Samor, B ^a   Michalski, C ^b   Brandin, M P ^b   Andre, M H ^b   Chtourou, S ^a   Tellier, Z ^b  

^a LFB Biotechnologies   (France)

^b Immunology Therapeutic Unit   (France)

Author keywords

FVIII immunogenicity; Haemophilia A; Very high purity FVIII; Von Willebrand factor

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

AGAR GEL ELECTROPHORESIS; ARTICLE; CONTROLLED STUDY; ELUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL FILTRATION; IMMUNOGENICITY; MOLECULAR WEIGHT; NANOFILTRATION; PRIORITY JOURNAL; PROTEIN BINDING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

BINDING, COMPETITIVE; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, AGAR GEL; FACTOR VIII; HEMOPHILIA A; HUMANS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROTEIN BINDING; VON WILLEBRAND FACTOR;

EID: 84862322638     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2011.01576.x     Document Type: Article

References (43)

1. Pipe SW: The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 2005; 3:1692-1701.
2. Tellier Z, Andre MH, Polack B: Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives. Clin Rev Allergy Immunol 2009; 37:125-134.
3. Iorio A, Halimeh S, Holzhauer S, et al.: Rate of inhibitor development in previously-untreated hemophilia a patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review. J Thromb Haemost 2010; 8:1256-1265.
4. Gensana M, Altisent C, Aznar JA, et al.: Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7:369-374.
5. Terraube V, O'Donnell JS, Jenkins PV: Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia 2009; 16:3-13.
6. Astermark J, Lacroix-Desmazes S, Reding MT: Inhibitor development. Haemophilia 2008; 14(Suppl 3):36-42.
7. Behrmann M, Pasi J, Saint-Remy JM, et al.: Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88:221-229.
8. Dasgupta S, Repesse Y, Bayry J, et al.: VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109:610-612.
9. Delignat S, Dasgupta S, Andre S, et al.: Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica 2007; 92:1423-1426.
10. Lacroix-Desmazes S, Moreau A, Sooryanarayana, et al.: Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999; 5:1044-1047.
11. Chtourou S, Porte P, Nogre M, et al.: A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates. Vox Sang 2007; 92:327-337.
12. Mazurier C, Parquet-Gernez A, Goudemand M: [Enzyme-linked immunoabsorbent assay of factor VIII-related antigen. Interest in study of Von Willerbrand's disease (author's transl)]. Pathol Biol (Paris) 1977; 25(Suppl):18-24.
13. Girma JP, Fressinaud E, Houllier A, et al.: Assay of factor VIII antigen (VIII:CAg) in 294 haemophilia A patients by a new commercial ELISA using monoclonal antibodies. Haemophilia 1998; 4:98-103.
14. Mazurier C, Jorieux S, de Romeuf C, et al.: In vitro evaluation of a very-high-purity, solvent/detergent-treated, von Willebrand factor concentrate. Vox Sang 1991; 61:1-7.
15. Jorieux S, Fressinaud E, Goudemand J, et al.: Conformational changes in the D' domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment. Blood 2000; 95:3139-3145.
16. Mazurier C, Gaucher C, Jorieux S, et al.: Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: consequences for therapy and genetic counselling. Br J Haematol 1990; 76:372-379.
17. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, et al.: A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83:107-113.
18. Caron C, Hilbert L, Vanhoorelbeke K, et al.: Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease. Br J Haematol 2006; 133:655-663.
19. Allen S, Abuzenadah AM, Blagg JL, et al.: Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood 2000; 95:2000-2007.
20. Hilbert L, Jorieux S, Proulle V, et al.: Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity. Br J Haematol 2003; 120:627-632.
21. Hilbert L, D'Oiron R, Fressinaud E, et al.: First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene. J Thromb Haemost 2004; 2:2271-2273.
22. Jorieux S, Gaucher C, Goudemand J, et al.: A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization. Blood 1998; 92:4663-4670.
23. Mazurier C, Meyer D: Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease - results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1996; 76:270-274.
24. Auerswald G, Spranger T, Brackmann HH: The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88:EREP05.
25. Bidlingmaier C, Manner D, Halimeh S, et al.: Influence of FVIII products, viral inactivation and dosage regimens on meaningful inhibitor development in children with severe hemophilia A: results of a non-concurrent cohort study. J Thromb Haemost 2007; 7:525-526.
26. Chalmers EA, Brown SA, Keeling D, et al.: Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13:149-155.
27. Ettingshausen CE, Kreuz W: Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006; 12(Suppl 6):102-106.
28. Goudemand J, Rothschild C, Demiguel V, et al.: Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107:46-51.
29. Kallas A, Talpsep T: von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7:375-380.
30. Strauss T, Ravid B, Martinowitz U, et al.: Early exposure to recombinant factor concentrates may increase inhibitor development: a single center cohort study. Haemophilia 2008; 14:52.
31. Wight J, Paisley S: The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9:418-435.
32. Mannucci PM, Gringeri A, Peyvandi F, et al.: Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13(Suppl 5):65-68.
33. Orsini F, Rotschild C, Beurrier P, et al.: Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90:1288-1290.
34. Kaufman RJ, Pipe SW: Regulation of factor VIII expression and activity by von Willebrand factor. Thromb Haemost 1999; 82:201-208.
35. Goudemand J, Laurian Y, Calvez T: Risk of inhibitors in haemophilia and the type of factor replacement. Curr Opin Hematol 2006; 13:316-322.
36. Berntorp E: Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance? Haematologica 2003; 88:EREP03.
37. Sadler JE, Budde U, Eikenboom JC, et al.: Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4:2103-2114.
38. Wise RJ, Dorner AJ, Krane M, et al.: The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem 1991; 266:21948-21955.
39. Fischer BE, Kramer G, Mitterer A, et al.: Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res 1996; 84:55-66.
40. Koppelman SJ, van Hoeij M, Vink T, et al.: Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996; 87:2292-2300.
41. Lin Y, Yang X, Chevrier MC, et al.: Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 2004; 10:459-469.
42. Vlot AJ, Koppelman SJ, van den Berg MH, et al.: The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995; 85:3150-3157.
43. Dargaud Y, Meunier S, Negrier C: Haemophilia and thrombophilia: an unexpected association! Haemophilia 2004; 10:319-326.